Not yet. The pLADD neoantigen-vaccine program uses the listeria vector (#msg-136838891).
Also, JNJ has not (yet) thrown in the towel on the NSCLC trial involving "first-generation" LADD, although they did stop the trial using PSA-targeted LADD in prostate cancer.